The Effect of 0.120noprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs

Journal of Veterinary Medical Science

Dorit RAZ¹  George N. LAMBROU²  Phillip H. KASS³  Christine PERCICOT²  Ron OFRI¹ 

[1] Koret School of Veterinary Medicine, Hebrew University of Jerusalem;Ophthalmic Research Unit, CIBA Vision AG;School of Veterinary Medicine, University of California

关键词: canine;    glaucoma;    unoprostone isopropyl;   

DOI  :  10.1292/jvms.62.1313

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(8)Cited-By(9)Rescula (0.120noprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49 ± 2.02 mm Hg in control eyes to 15.49 ± 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.

【 授权许可】

Unknown